AIRS
AirSculpt Technologies, Inc.
AIRS trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over AIRS overall, supported by stronger fundamentals and stronger valuation.
AIRS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Weak |
AIRS's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AIRS PE Valuation
AIRS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AIRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect AIRS's losses to grow, with revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AIRS on the outlook, with more favorable earnings and revenue expectations.
AIRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.13 | +$0.16 |
| Q2 2026 | -$0.18 | +$0.06 |
| Q1 2026 | -$0.17 | +$0.12 |
| Q4 2025 | -$0.19 | -$0.05 |
| Q3 2025 | -$0.29 | -$0.15 |
| Q2 2025 | -$0.24 | -$0.17 |
| Q1 2025 | -$0.29 | -1550% |
| Q4 2024 | -$0.14 | -$0.06 |
AIRS is still losing money, but far less than before: $0.13 per share over the past year, against $0.29 at its worst in early 2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AIRS on earnings quality, reporting a profit while its opponent remains loss making.
AIRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $31.9M | -8.7% |
| Q2 2026 | $42.9M | -2.5% |
| Q1 2026 | $39.4M | 0% |
| Q4 2025 | $33.4M | -15% |
| Q3 2025 | $35M | -18% |
| Q2 2025 | $44M | -14% |
| Q1 2025 | $39.4M | -17% |
| Q4 2024 | $39.2M | -18% |
AIRS's revenue has slid since its 2023 peak: $32M last quarter, down 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13% | +15 points |
| Q2 2026 | -0.1% | -1.9 points |
| Q1 2026 | -4.6% | -0.5 points |
| Q4 2025 | -3% | +7.5 points |
| Q3 2025 | -28% | -19 points |
| Q2 2025 | 1.8% | +12 points |
| Q1 2025 | -4% | -27 points |
| Q4 2024 | -11% | -14 points |
AIRS's operating margin was −13% last quarter, up 15 points from the same quarter a year ago, near the bottom of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AIRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AIRS on profitability, with a higher operating margin.
AIRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.7M | -$3.3M |
| Q2 2026 | -$1.5M | -131% |
| Q1 2026 | $5.2M | +$6.3M |
| Q4 2025 | -$2.6M | -$1.8M |
| Q3 2025 | -$405K | +$2.7M |
| Q2 2025 | $4.7M | +$5.3M |
| Q1 2025 | -$1M | -157% |
| Q4 2024 | -$815K | -127% |
AIRS has burned cash in six of the last eight quarters: −$3M over the past year, against $2M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AIRS on cash generation, producing positive trailing cash flow while its opponent burns cash.
AIRS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.3x | High |
| Q1 2026 | 35.7x | High |
| Q4 2025 | 39.0x | High |
| Q2 2025 | 12.3x | High |
| Q4 2024 | 6.1x | High |
| Q3 2024 | 4.2x | High |
| Q2 2024 | 3.1x | Elevated |
| Q1 2024 | 2.0x | Moderate |
AIRS's net debt is about 4.3 years of its operating earnings (EBITDA), down from 6.1 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over AIRS on leverage, with a lower net debt burden relative to earnings.
AIRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.5 | Neutral |
| Stochastic | 7.2 | Oversold |
AIRS's weekly RSI is 32 (neutral) and its Stochastic is 7 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AIRS PE vs Healthcare Sector
| Metric | AIRS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AIRS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AIRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.35 | 47% below |
| 20 week MA | $2.74 | 74% below |
| 50 week MA | $2.95 | 76% below |
| 100 week MA | $4.09 | 82% below |
| 200 week MA | $5.09 | 86% below |
AIRS is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AIRS on trend strength, trading above more of its moving averages.
AIRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $15.9 | $14.5 | -8.7% |
| 2022 | $14.5 | $3.32 | -77% |
| 2023 | $3.32 | $7.49 | +126% |
| 2024 | $7.49 | $5.58 | -26% |
| 2025 | $5.58 | $2.03 | -64% |
| 2026 YTD | $2.03 | $0.72 | -65% |
AIRS's yearly returns have swung widely, from +126% in 2023 to −77% in 2022. It's down 65% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AIRS on returns for 2026, with the stronger performance.